For operating partners and portfolio managers
Know which companies will hit their plan, and what closes the gap for the rest
EVOS reads the public evidence on a company (patents, filings, competitor moves) and returns the analysis an analyst team would take weeks to produce. Test a growth story in days instead of quarters.
The return now depends on growth you can't see coming
Growth targets in PE plans have roughly doubled in a decade. Most portfolio reviews still look backward at reported revenue. By the time a gap shows in the numbers, the time to close it has gone.
Delay pushes the growth curve back two to four years. On a five-year hold, that is most of the value creation plan.
Placeholder: Bain chart component from rapidalpha.com, if Matthew agrees to share it across sites.
Four jobs EVOS does for a fund
Diligence
Technology and IP evidence on a target within deal timelines. See whether the growth story holds before you price it.
Watching a company you own
The gap between the growth the plan needs and the growth it's on track for, as a number and a date.
IP risk
Where the patents protecting the plan expire, who's filing around them, and what that means for revenue.
Entering a new market
A fragmented market mapped (players, financials, products) with the consolidation moves visible early.
Four pages on a company you own
- The growth gap, as a number and a date
- Where the market is moving, and what the plan has missed
- IP risk on the plan you've already funded
- Whether the return still works on this timeline
Built from public information only, so nothing needs an NDA.
Secondary link "See a sample report →" only if a redacted report is approved
One view across every company you own
Each company's goal, gap and bets roll up into one picture, so you can see where to put operating attention, and which management teams need help turning a number into a plan.
We pointed the method at Roche's public record. It called the revenue mix seven years early.
Half of Roche Pharmaceuticals' revenue was heading off patent. The pipeline evidence already showed what would replace it.
Name one company. We'll show you its gap.
Bring a company you own or are looking at. We'll run it through EVOS on public data before the demo.